Ken Kobayashi
Chief Tech/Sci/R&D Officer chez PYXIS ONCOLOGY, INC.
Profil
Ken Kobayashi is currently the Chief Medical Officer at Pyxis Oncology, Inc. Prior to this, he held positions as VP-Early Oncology Development & Clinical Research at Pfizer Inc. and Senior Vice President-Clinical Development at Kinnate Biopharma, Inc. He received his undergraduate degree from the University of Washington and his doctorate from the Feinberg School of Medicine.
Postes actifs de Ken Kobayashi
| Sociétés | Poste | Début |
|---|---|---|
| PYXIS ONCOLOGY, INC. | Chief Tech/Sci/R&D Officer | 27/11/2023 |
Anciens postes connus de Ken Kobayashi
| Sociétés | Poste | Fin |
|---|---|---|
| KINNATE BIOPHARMA INC. | Chief Tech/Sci/R&D Officer | 02/03/2023 |
| PFIZER, INC. | Corporate Officer/Principal | - |
Formation de Ken Kobayashi
| University of Washington | Undergraduate Degree |
| Feinberg School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| PYXIS ONCOLOGY, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Kinnate Biopharma, Inc.
 Kinnate Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Kinnate Biopharma, Inc. operates as a biopharmaceutical company engaged in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company was founded by Stephen W. Kaldor and Eric A. Murphy in January 2018 and is headquartered in San Diego, CA. | Health Technology |
